Designing Adjuvant Formulations to Promote Immunogenicity and Protective Efficacy of Leptospira Immunoglobulin-Like Protein A Subunit Vaccine

Techawiwattanaboon T, Courant T, Brunner L, et al. D. Front Cell Infect Microbiol. 2022;12:918629. doi:10.3389/fcimb.2022.918629

VFI headquarters and Geneva laboratories

Rue du Champ-Blanchod 4
1228 Plan-les-Ouates
Switzerland

VFI Lausanne laboratories

Route de la Corniche 5
1066 Epalinges
Switzerland

contact@vformulation.org
VFI on LinkedIn

© 2025 Vaccine Formulation Institute